EAU 2014 - Poster: Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials

STOCKHOLM, SWEDEN (UroToday.com) - Presented by T. Tammela,¹ C. Massard,² P. Bono,³ P. Langmuir,⁴ J. Aspegren,⁵ A. Vuorela,⁵ M.V.J. Mustonen,⁵ and K. Fizazi² at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

¹Tampere University Hospital, Dept. of Urology, Tampere, Finland, ²Institute Gustave Roussy, University of Paris Sud, Dept. of Cancer Medicine, Villejuif, France, ³Helsinki University Hospital, Dept. of Oncology, Helsinki, Finland, ⁴Endo Pharmaceuticals, Dept. of Clinical Development, Malvern, United States, ⁵Orion Corporation Orion Pharma, Dept. of Research and Development, Espoo, Finland